{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T02:51:01Z","timestamp":1768445461128,"version":"3.49.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,1,3]],"date-time":"2018-01-03T00:00:00Z","timestamp":1514937600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asian Journal of Urology"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.ajur.2018.01.001","type":"journal-article","created":{"date-parts":[[2018,1,6]],"date-time":"2018-01-06T12:29:01Z","timestamp":1515241741000},"page":"210-214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Asynchronous abdominal wall and sigmoid metastases in clear cell renal cell carcinoma: A case report and literature review"],"prefix":"10.1016","volume":"6","author":[{"given":"Fangyuan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengjie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianye","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajur.2018.01.001_bib1","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMra043172","article-title":"Renal cell carcinoma","volume":"353","author":"Cohen","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajur.2018.01.001_bib2","first-page":"69","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ajur.2018.01.001_bib3","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(09)60229-4","article-title":"Renal cell carcinoma","volume":"373","author":"Rini","year":"2009","journal-title":"The Lancet"},{"key":"10.1016\/j.ajur.2018.01.001_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2015.11.001","article-title":"Characterization of clear cell renal cell carcinoma by gene expression profiling","volume":"34","author":"Thibodeau","year":"2016","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ajur.2018.01.001_bib5","first-page":"12617","article-title":"Renal cell carcinoma: long-term survival and late recurrence","author":"McNichols","year":"1981","journal-title":"J Urol"},{"key":"10.1016\/j.ajur.2018.01.001_bib6","first-page":"21273","article-title":"Recurrent renal cell carcinoma after 45 years","author":"Tapper","year":"1997","journal-title":"Clin Imaging"},{"key":"10.1016\/j.ajur.2018.01.001_bib7","first-page":"651086","article-title":"Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy","author":"Kroeger","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.ajur.2018.01.001_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2015.11.022","article-title":"Local salvage therapy for late (\u22652 years) metastatic and local relapse of renal cell cancer is a potentially curative treatment irrespective of the site of recurrence","volume":"34","author":"Gr\u00fcllich","year":"2016","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ajur.2018.01.001_bib9","first-page":"84405","article-title":"Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy","author":"Ljungberg","year":"1999","journal-title":"BJU Int"},{"key":"10.1016\/j.ajur.2018.01.001_bib10","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1007\/s10147-014-0775-2","article-title":"Different clinicopathological features between patients who developed early and late recurrence following surgery for renal cell carcinoma","volume":"20","author":"Fujii","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.ajur.2018.01.001_bib11","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0090-4295(00)00639-7","article-title":"Renal cell carcinoma metastatic to the pancreas: a single-institution series and review of the literature","volume":"56","author":"Kassabian","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.ajur.2018.01.001_bib12","first-page":"124","article-title":"Metastatic renal cell cancer presenting as a breast mass","volume":"10","author":"Pathe","year":"2012","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.ajur.2018.01.001_bib13","first-page":"132","article-title":"A solitary polypoid gastric metastasis 20 years after renal cell carcinoma: an event to be considered, and a brief review of the literature","volume":"105","author":"Onorati","year":"2013","journal-title":"Pathologica"},{"key":"10.1016\/j.ajur.2018.01.001_bib14","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/bju.12246","article-title":"Time to recurrence is a significant predictor of cancer-specific survival after recurrence in patients with recurrent renal cell carcinoma \u2014 results from a comprehensive multi-centre database (CORONA\/SATURN-Project)","volume":"112","author":"Brookman-May","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.ajur.2018.01.001_bib15","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.urology.2011.05.012","article-title":"Outcomes and clinicopathologic variables associated with late recurrence after nephrectomy for localized renal cell carcinoma","volume":"78","author":"Kim","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.ajur.2018.01.001_bib16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.juro.2014.07.011","article-title":"Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma","volume":"193","author":"Santoni","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.ajur.2018.01.001_bib17","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrc1098","article-title":"The pathogenesis of cancer metastasis: the \u2018seed and soil\u2019 hypothesis revisited","volume":"3","author":"Fidler","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ajur.2018.01.001_bib18","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1159\/000463826","article-title":"Late recurrence of renal-cell carcinoma after nephrectomy","volume":"10","author":"Nakano","year":"1984","journal-title":"Eur Urol"},{"key":"10.1016\/j.ajur.2018.01.001_bib19","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.juro.2010.09.100","article-title":"Clinical characteristics and outcomes of patients with recurrence 5 years after nephrectomy for localized renal cell carcinoma","volume":"185","author":"Adamy","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.ajur.2018.01.001_bib20","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.eururo.2015.01.005","article-title":"EAU guidelines on renal cell carcinoma: 2014 update","volume":"67","author":"Ljungberg","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.ajur.2018.01.001_bib21","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2002.20.1.289","article-title":"Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma","volume":"20","author":"Motzer","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajur.2018.01.001_bib22","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1200\/JCO.2005.03.206","article-title":"Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma","volume":"23","author":"McDermott","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajur.2018.01.001_bib23","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.critrevonc.2008.08.002","article-title":"The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce","volume":"69","author":"Bellmunt","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ajur.2018.01.001_bib24","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajur.2018.01.001_bib25","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S1470-2045(13)70093-7","article-title":"Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial","volume":"14","author":"Motzer","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ajur.2018.01.001_bib26","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","article-title":"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial","volume":"17","author":"Choueiri","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ajur.2018.01.001_bib27","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ajur.2018.01.001_bib28","first-page":"91","article-title":"Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and\/or sorafenib","volume":"4","author":"Coppin","year":"2010","journal-title":"Biologics"},{"key":"10.1016\/j.ajur.2018.01.001_bib29","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.5301\/tj.5000268","article-title":"Very late recurrence of renal cell carcinoma experiencing long-term response to sunitinib: a case report","volume":"101","author":"Messina","year":"2015","journal-title":"Tumori"},{"key":"10.1016\/j.ajur.2018.01.001_bib30","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajur.2018.01.001_bib31","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.clgc.2015.07.005","article-title":"Is late recurrence a predictive clinical marker for better sunitinib response in metastatic renal cell carcinoma patients?","volume":"13","author":"Bozkurt","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ajur.2018.01.001_bib32","doi-asserted-by":"crossref","first-page":"E553","DOI":"10.1111\/j.1464-410X.2012.11246.x","article-title":"Late recurrence of renal cell carcinoma >5 years after surgery: clinicopathological characteristics and prognosis","volume":"110","author":"Park","year":"2012","journal-title":"BJU Int"}],"container-title":["Asian Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214388218300018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214388218300018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:32:13Z","timestamp":1762000333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214388218300018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S2214388218300018"],"URL":"https:\/\/doi.org\/10.1016\/j.ajur.2018.01.001","relation":{},"ISSN":["2214-3882"],"issn-type":[{"value":"2214-3882","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Asynchronous abdominal wall and sigmoid metastases in clear cell renal cell carcinoma: A case report and literature review","name":"articletitle","label":"Article Title"},{"value":"Asian Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajur.2018.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}